Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
Synthekine
BeOne Medicines
Boehringer Ingelheim
National Institutes of Health Clinical Center (CC)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
Gilead Sciences
BioNTech SE
Bristol-Myers Squibb
AbbVie
Seagen Inc.
Genmab
Merck Sharp & Dohme LLC
Seagen Inc.
PrECOG, LLC.
Hunan Province Tumor Hospital
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Boehringer Ingelheim
AstraZeneca
AstraZeneca
Xencor, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Mirati Therapeutics Inc.
Hoosier Cancer Research Network
Eli Lilly and Company
BioNTech SE
Hoffmann-La Roche
Merck Sharp & Dohme LLC
AstraZeneca
Hoffmann-La Roche
AstraZeneca
Merck Sharp & Dohme LLC
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Incyte Corporation